Treatment Investigational New Drug experience with Survanta (beractant).

From September 1989 through July 1991, before commercial availability, Survanta (beractant intratracheal suspension), a modified bovine-derived surfactant used for prevention and treatment of neonatal respiratory distress syndrome, was made available to 231 neonatal intensive care units in the United States and Canada under a Treatment Investigational New Drug protocol. Results of this open clinical experience are reported. Investigators could give one dose of Survanta soon after birth to neonates weighing 600 to 1250 g (prevention strategy).

A comparison of prone and sitting on heart rates, respiration rates, and arterial oxygen saturation levels of premature infants.

: The purpose of this study was to compare the effects of prone and sitting on the heart rates, respiration rates, and arterial oxygen saturation levels of premature infants. The positioning device used for sitting the infants was the premature infant seat, an experimental seat developed by the principal investigator. Thirty premature infants' heart rates, respiration rates, and arterial oxygen saturation levels were recorded in three 30-minute periods: 1) prone-baseline, 2) sitting in the premature infant seat, and 3) pronerecovery.